Ratings
0
Nobody has rated this yet. Be the first!
Works
3
Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.
Adaptive immunity in rheumatic diseases: bystander or pathogenic player?
